Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/Hisun to collaborate in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China

Pfizer has announced it is to work with Zhejiang Hisun Pharmaceuticals to develop and market generic drugs in China.

The companies have signed a memorandum of understanding on their intention to establish a joint venture with a focus on research, development and commercialisation of off-patent medicines to help build the presence of both firms in the country.

Both parties can contribute existing products and assets to provide a platform for the collaboration.

The move follows a similar agreement Pfizer signed with Chinese company Shanghai Pharmaceuticals, which included distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities.

According to Pfizer, branded generics account for 60 per cent of the domestic market in China, with the country expected to become the world's second-largest pharmaceutical market by 2015.

Hua Bai, CEO and president of Hisun Pharmaceuticals, stated that such deals were the way forward for the company. He said: "Collaborating with the world's leading pharmaceutical companies to form potential joint ventures is a strategy being adopted by Hisun."

6th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics